EMvision Medical Devices Stock Price | Stock Quote, News, and History
Isabella Bartlett 
- All
- Buy
- Hold
- Sell
| 2024 | 2025 | |
|---|---|---|
| Revenue | 8 | 7 |
| Dividend | 0.00 | 0.00 |
| Dividend Yield (in %) | - | - |
| EPS | -0.05 | -0.09 |
| P/E Ratio | -39.80 | -22.31 |
| EBIT | -4 | -7 |
| EBITDA | -4 | -7 |
| Net Profit | -4 | -7 |
| Net Profit Adjusted | -4 | - |
| Pre-Tax Profit | -4 | -7 |
| Net Profit (Adjusted) | - | - |
| EPS (Non-GAAP) ex. SOE | - | - |
| EPS (GAAP) | -0.05 | - |
| Gross Income | 0 | 1 |
| Cash Flow from Investing | 0 | 0 |
| Cash Flow from Operations | -3 | -7 |
| Cash Flow from Financing | 10 | 10 |
| Cash Flow per Share | 0.00 | - |
| Free Cash Flow | -2 | - |
| Free Cash Flow per Share | 0.00 | - |
| Book Value per Share | 0.20 | - |
| Net Debt | -16 | - |
| Research & Development Exp. | 3 | 3 |
| Capital Expenditure | 0 | 0 |
| Selling, General & Admin. Exp. | - | - |
| Shareholder’s Equity | 12 | 15 |
| Total Assets | 14 | 18 |
| Previous Quarter | Current Quarter | Next Quarter | Current Year ending 06/30/24 | Next Year ending 06/30/25 | |
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | - | - | - | 1 | 1 |
| Average Estimate | - | - | - | -0.051 AUD | -0.091 AUD |
| Year Ago | - | - | - | -0.050 AUD | -0.051 AUD |
| Publish Date | - | - | - | - | - |
| Revenue Estimates | |||||
| No. of Analysts | - | - | - | 1 | 1 |
| Average Estimate | - | - | - | 8 AUD | 7 AUD |
| Year Ago | - | - | - | 7 AUD | 8 AUD |
| Publish Date | - | - | - | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
*Yield of the Respective Date
EMvision Medical Devices Ltd. engages in the development & commercialization of medical imaging technology. The company was founded on July 11, 2017, and is headquartered in Brisbane, Australia.
Risk- Low
- Medium
- High
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.
| Owner | in % |
|---|---|
| Freefloat | 65.23 |
| Scott Kirkland | 4.95 |
| Ryan Laws | 4.17 |
| Ronald Peter Weinberger, PhD | 2.70 |
| John Keep | 2.65 |
| Hillridge Pty Ltd. | 2.18 |
| Paul Raymond Brown | 1.74 |
| Jm Starcevich Investments Pty Ltd. | 1.58 |
| The University of Queensland | 1.54 |
| Busso Holdings Pty Ltd. | 1.49 |
| Glensburg Pty Ltd. | 1.43 |
| Bryant James McLarty | 1.38 |
| Walsh Prestige Pty Ltd. | 1.35 |
| Stuart Crozier, PhD | 1.34 |
| Martin Kolev | 1.28 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
